Tema Etfs LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Tema Etfs LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 16,323 shares of the biopharmaceutical company's stock, valued at approximately $3,841,000. Alnylam Pharmaceuticals makes up approximately 1.6% of Tema Etfs LLC's portfolio, making the stock its 24th largest position.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ALNY. Larson Financial Group LLC raised its position in shares of Alnylam Pharmaceuticals by 187.2% during the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares during the period. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $33,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. Colonial Trust Co SC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth approximately $35,000. Finally, IFP Advisors Inc lifted its stake in Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 47 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Up 0.3%

Alnylam Pharmaceuticals stock traded up $0.90 during trading hours on Wednesday, reaching $292.58. The company had a trading volume of 930,234 shares, compared to its average volume of 914,931. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 12-month low of $146.79 and a 12-month high of $304.39. The company has a 50-day moving average price of $255.71 and a 200 day moving average price of $253.88. The firm has a market cap of $38.15 billion, a price-to-earnings ratio of -134.83 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the firm posted ($0.16) earnings per share. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALNY has been the subject of a number of research reports. HC Wainwright reiterated a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Scotiabank upped their price objective on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a research report on Monday, March 31st. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. StockNews.com upgraded Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Bank of America upped their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have given a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $319.17.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.